Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea Limited - Depositary Receipt ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

Regal Partners has written off its entire investment in Opthea, which contributed to funds under management (FUM) taking an 8.3% hit in the March 2025 quarter.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.